Diamyd Medical

"With this capital injection, we now have financing until 2025", says Ulf Hannelius, CEO of Diamyd Medical. "The outcome of the rights issue, given the prevailing financial market and global situation, is satisfactory and means that we continue according to plan. I would like to thank existing and new shareholders that we this year,  including the previous rights issue, in a difficult market, were able to raise over SEK 150 million. This is a significant sign of trust that we will do our utmost to honour. Partners such as JDRF and strategic long-term investors are of course extremely important in these times, and with the tailwind that we and the diabetes field have, and with strengthened funding, the conditions for various types of collaboration have been further strengthened."

The Board of Directors in Diamyd Medical resolved on September 20, 2023, with the subsequent approval by the extraordinary general meeting in the Company on October 10, 2023, a rights issue of up to approximately SEK 243 million.

Final Outcome
The Rights Issue is comprised of 28,594,104 units, of which 185,407 A-units and 8,030,441 B-units, corresponding to approximately 29 percent of the offered units, have been subscribed for with unit rights. Additionally, applications for subscription of 949,834 B-units without unit rights, corresponding to approximately 3 percent of the offered units, have been received. Thus, the subscriptions by exercise of unit rights and the applications for subscription without unit rights correspond to approximately 32 percent. Through the Rights Issue, the Company will thus receive issue proceeds of approximately SEK 78 million before the deduction of costs attributable to the Rights Issue. Subscribers in the Rights Issue include the Chairman of the Board of Directors and founder Anders Essen-Möller (SEK 7 million), the Company's largest shareholder Bertil Lindkvist (SEK 6.8 million), and other Senior Executives and members of the Board of Directors (SEK 900 thousand).

Notice of allotment
All those who have subscribed for units without unit rights will be allocated units in accordance with the principles set out in the EU growth prospectus which was approved and registered by the Swedish Financial Supervisory Authority on October 16, 2023. Notice of allotment to the persons who subscribed for units without unit rights is expected to be distributed on November 2, 2023. Subscribed and allotted units shall be paid in cash within three banking days in accordance with the instructions on the settlement note sent to the subscriber. Subscribers who have subscribed for units through a nominee will receive notification of allocation in accordance with their respective nominee's procedures. Only those who have been allotted units will be notified.

Number of shares and share capital
Through the Rights Issue, Diamyd Medical's share capital will increase by SEK 929,595.0148, from SEK 8,700,150.3488 to SEK 9,629,745.3636, and the number of shares will increase by 9,165,682 shares, from 85,782,314 shares to 94,947,996 shares, resulting in that the number of A-shares after the Rights Issue will amount to 2,741,630 and the number of B-shares will amount to 92,206,366. The last day of trading in paid subscribed units (Sw. BTU B) is expected to be November 20, 2023. The new B-shares, TO3 B and TO4 B subscribed for with and without unit rights are expected to be traded on Nasdaq First North Growth Market around week 47, 2023.

Advisors
G&W Fondkommission acts as Financial Advisor to Diamyd Medical in connection with the Rights Issue.
Advokatfirman Delphi is Legal Advisor to the Company and Aqurat Fondkommission AB has been appointed as

Issuer Agent.

About Diamyd Medical
Diamyd Medical develops precision medicine therapies for Type 1 Diabetes. Diamyd^® is an antigen-specific immunotherapy for the preservation of endogenous insulin production. DIAGNODE-3, a confirmatory Phase III trial is actively recruiting patients with recent-onset Type 1 Diabetes in eight European countries and in the US. Significant results have previously been shown in a large genetically predefined patient group in a largescale meta-analysis as well as in the Company's European Phase IIb trial DIAGNODE-2, where Diamyd^® was administered directly into a lymph node in children and young adults with recently diagnosed Type 1 Diabetes. A biomanufacturing facility is being set up in Umeå for the manufacture of recombinant GAD65, the active ingredient in the antigen-specific immunotherapy Diamyd^®. Diamyd Medical also develops the GABA-based investigational drug Remygen^® as a therapy for regeneration of endogenous insulin production and to improve hormonal response to hypoglycaemia. Diamyd Medical is one of the major shareholders in the stem cell company NextCell Pharma AB as well as in the artificial intelligence company MainlyAI AB.

Diamyd Medical's B-share is traded on Nasdaq First North Growth Market under the ticker DMYD B. FNCA Sweden AB is the Company's Certified Adviser.